Fig. 7: Cost savings analysis. | Nature Communications

Fig. 7: Cost savings analysis.

From: Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial

Fig. 7

A Percentage of molecular test reduction vs. biomarker prevalence using the high-sensitivity model presented in Fig. 4A (88.7% sensitivity, 31.8% specificity). In this scenario, patients predicted biomarker negative would be de-prioritized from molecular testing (i.e., rule-out patients in a clinical study with pre-defined sites like ANNAR). B Percentage of FGFR+ detected patients vs. percentage of patients receiving molecular test using different operating points of our FGFR model compared to without AI. Each curve represents enhancement for a given biomarker prevalence. Red and blue dotted lines represent the “Low” and “High” operating points of the simulated 3-tier model presented in Fig. 4D. C Prevalence enrichment using the simulated 3-tier model. Note that “High” vs. Baseline shows enrichment in the”High” group compared to baseline prevalence, whereas “High” vs “Low” shows prevalence enrichment of “High” group vs. “Low” group.

Back to article page